(Clinicaltrials.gov identifier: NCT01905033)

2011 –  2016: The MARS Sepsis Consortium is a prospective observational cohort study designed to produce molecular information relevant to sepsis diagnosis and management. Immunexpress is a full partner in the collaborative Consortium. The Consortium recruited 8,603 critical care patients with signs of Systemic Inflammatory Response Syndrome (SIRS) across two tertiary hospitals in the Netherlands: the Academisch Medisch Centrum (AMC) in Amsterdam, and the University Medical Centre Utrecht (UMCU). Immunexpress is continuing collaborative sepsis clinical research at both study sites.

Dr. Tom van der Poll

Tom van der Poll is Professor of Medicine and Chair of the Department of Medicine in the Academic Medical Center, University of Amsterdam, the Netherlands. Van der Poll is board certified in Internal Medicine and Infectious Diseases. Van der Poll’s research focuses on pneumonia and sepsis, particularly on pathogenesis, the host response and biomarkers. He published > 800 articles on this topic. Van der Poll has served as a member of Data Safety and Clinical Monitoring Boards of several pivotal phase III sepsis and pneumonia trials evaluating immunomodulatory agents. He is a member (past Chair) of the International Sepsis Forum.

2019 – present: The Gene Expression Objective Definition of Early Sepsis In Children (GEODESIC) study is a collaborative pilot study at the Seattle Children’s Hospital between Professor Jerry Zimmerman and Immunexpress. Immunexpress and the Seattle Children’s Research Institute are jointly funding this study.

Dr. Jerry Zimmerman

Jerry J. Zimmerman, MD, PhD, is an attending physician in the Pediatric Intensive Care Unit at Seattle Children's Hospital. He is Professor of Pediatrics and Anesthesiology at the University of Washington School of Medicine. Zimmerman has been chair of the Scientific Advisory Committee for Children's Hospital Clinical Research Center since its inception and is a member of the Steering Committee for the Center for Clinical and Translational Research. He is a charter member of the American College of Critical Care Medicine and is Treasurer of the Society of Critical Care Medicine and is a member of the Executive Committee.

With Bradley Fuhrman, Zimmerman is co-editor of the current premier textbook for the field, Pediatric Critical Care, now in its 4th edition. Additionally, Zimmerman serves on the editorial boards for Critical Care Medicine and Pediatric Critical Care Medicine, and is book review editor for both journals. He also provides ad hoc review for a number of other journals. Zimmerman is interested in the disequilibrium between the systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome that occurs as an important aspect of pathophysiology in critical illness. He is interested in the integrated role of neurological, endocrinologic and inflammatory cross-talk, particularly involving reactive oxygen species and fatty acidderived mediators and their effect on metabolism. Zimmerman was chosen as a charter principal investigator for the recently established Collaborative Pediatric Critical Care Research Network.

2013- 2018: Intermountain Healthcare acted as the coordinating trial and data collection site for the FDA clearance studies of SeptiCyte® technology, including the on-site real-time studies for SeptiCyte® LAB, and has a long history of interaction with Immunexpress. This collaboration has resulted in multiple papers and publications ranging from assay performance trials through to health econometric modeling.

Dr. Bert Lopansri

Bert K. Lopansri, MD, FIDSA is a board certified, academic Infectious Diseases Specialist at Intermountain Healthcare hospitals. He serves as Chief of the Intermountain Division of Infectious Diseases and Medical Director for the Intermountain Central Microbiology Laboratory. He also directs the Infectious Diseases Research and Epidemiology Laboratory located at LDS Hospital. His research interests are in diagnostic microbiology and he has participated in clinical trials evaluating novel, rapid, molecular tests. He also has interests in the epidemiology and outcomes of infections from Clostridium difficile and antibiotic resistant bacteria. Dr. Lopansri is an Associate Professor of Medicine at the University of Utah School of Medicine.

Dr. Russell Miller (formerly of Intermountain Medical Center)

Russell R. Miller, MD, MPH, FCCM is an Intensivist and Medical Director of Critical Care at FirstHealth of the Carolinas in Pinehurst, NC. Previously, he was Chair of the Critical Care Development Team for Intermountain Healthcare and Director of the Respiratory ICU at Intermountain Medical Center. He did undergraduate training at Duke University, medical and residency training in SE United States, and then a fellowship in Pulmonary and Critical Care Medicine at Vanderbilt University. His academic interests have included sepsis, pneumonia and associated lung injury, sedation and delirium in the ICU, and ICU mobility. Dr. Miller also directs quality improvement and best practice development within critical care for Intermountain Healthcare.

2011 – 2020: University College London and Immunexpress continue to collaborate in prospective observational cohort studies including in pneumonia, immunocompromised sepsis patients, UTIs, and on validation of gene expression biomarkers for bacterial and viral sepsis.

Dr. Mahdad Noursadeghi

Mahdad Noursadeghi is Professor of Infectious Diseases at University College London and Consultant in Infectious Diseases and Internal Medicine at University College London Hospital NHS Foundation Trust. He leads a research group, funded by the Wellcome Trust, UK Medical Research Council and UK National Institute for Health Research, focussing on systems level analysis of host responses to infection, with the aim of discriminating between protective and pathogenic immune responses that may inform the development of new therapies and novel approaches to patient stratification.

The NEPTUNE Clinical Study was the prospective arm of the clinical validation of SetiCyte® RAPID for the submission for FDA clearance.

Dr. Annette Esper

Dr. Esper received her undergraduate degree at the University of Texas at Austin. She earned her medical degree in 2002 from the University of Texas Medical School at Houston. She completed an Internal Medicine residency program in 2005 and a Pulmonary/Critical Care fellowship in 2008 at Emory University. In 2008, after completing fellowship, she joined the faculty at Emory University as an Assistant Professor of Medicine in the Division of Pulmonary, Allergy, and Critical Care. During her first two years on faculty she earned her Masters of Science in Clinical Research from the Laney Graduate School at Emory University. Dr. Esper is clinically active in pulmonary and critical care at Grady Memorial Hospital and serves as the medical director of the stepdown Intensive Care Unit at Grady Memorial Hospital.

Dr. Esper's research includes clinical and translational research in critically ill patients, with a specific interest in sepsis and the acute respiratory distress syndrome (ARDS). She has conducted research that evaluated disparities in sepsis and the impact of diabetes on ARDS development. Currently, her work focuses on translational research in sepsis-induced ARDS, where she is investigating the role of alveolar macrophage function and phenotype, and conducting biomarker and metabolomics studies in ARDS. In addition to her clinical and research work, she has the opportunity to teach medical students, residents and fellows in both the inpatient and outpatient settings.

Dr. Robert Balk

Dr. Balk went to the University of Missouri at Kansas City 6 year Medical School and received his BA in Biology in 1976 and the MD degree in 1978. He completed his internship and residency in internal medicine at the University of Missouri – Kansas City and went to the University of Arkansas For Medical Sciences for Fellowship training in Pulmonary and Critical Care Medicine. Dr. Balk is the J. Bailey Carter, MD Professor of Medicine at Rush Medical College and the Director of the Division of Pulmonary, Critical Care, and Sleep Medicine at Rush University Medical Center in Chicago, IL. Dr. Balk is the Associate Chief Medical Officer for Critical Care, the Director of Adult Cystic Fibrosis Program, the Medical Director of Adult ECMO program, and the Medical Director of the Perfusion Training Program of Rush University.

Dr. Balk’s major clinical and research interest have been focused on understanding the pathogenesis and defining management strategies for patients with sepsis, septic shock, the acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome. He is also interested in biomarkers in critical illness and the diagnosis and management of pneumonia.

Professor Luregn Schlapbach is an internationally recognized expert in sepsis and other life-threatening infectious and inflammatory conditions. He maintains a research program on Sepsis, Infection, and Inflammation in Critically Ill Children at the Child Health Research Centre, University of Queensland. He is Past Chair of the Australian and New Zealand Intensive Care Society Paediatric Study Group. Prof. Schlapbach`s research has focused on sepsis and life-threatening infections in critically ill neonates and children, including aspects such as epidemiology, sepsis markers, outcomes and genomics in this highly vulnerable patient group. He is interested in improving our understanding of why some children become critically unwell because of infections, and in developing better approaches to allow early recognition and targeted treatment of sepsis and severe infections in children.

Dr Adam Irwin is a NHMRC Emerging Leadership Fellow and conjoint Senior Lecturer in paediatric infectious disease at The University of Queensland and Queensland Children’s Hospital. His research focuses on early recognition of invasive infections and sepsis, and optimal use of antimicrobials including the most appropriate treatment of healthcare-associated and antimicrobial resistant infections in children. He is the co-chair of the Queensland Paediatric Sepsis Program which was awarded the Global Sepsis Alliance award in 2020.